Consensus on the treatment of allergic asthma with sublingual house dust mite immunotherapy in the field of pneumology

Expert Rev Respir Med. 2021 Oct;15(10):1245-1249. doi: 10.1080/17476348.2021.1942846. Epub 2021 Aug 18.

Abstract

Introduction: Many patients sensitized to mites remain symptomatic and uncontrolled despite traditional treatment. Sublingual immunotherapy (SLIT) has demonstrated to reduce the symptoms of allergic rhinitis, the need for additional drug treatments, and to reduce the number of moderate and severe exacerbations in patients with allergic asthma caused by mites that had not been adequately controlled.Areas covered: After reviewing the most recent literature, a scientific committee composed by five pneumologists experts in asthma proposed 41 items that addressed the diagnosis of allergic asthma caused by mites, the role of house dust mite (HDM) SLIT tablet in the therapeutic plan and in the control of the disease, and the profile of patients with asthma candidates for this therapy. Through a modified Delphi method, the items were send to 106 pneumologists involved in asthma to be agreed.Expert opinion: The high degree of consensus reached by the panel of pneumologists shows the importance of HDM SLIT tablet in the treatment of allergic asthma caused by mites, particularly taking into account that they barely use this therapy because until now they did not have a registered treatment with solid evidence of efficacy and safety.

Keywords: Allergy; asthma; immunotherapy; mites; subcutaneous; sublingual.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Dermatophagoides
  • Asthma* / diagnosis
  • Asthma* / therapy
  • Consensus
  • Humans
  • Pulmonary Medicine*
  • Pyroglyphidae
  • Sublingual Immunotherapy*

Substances

  • Antigens, Dermatophagoides